Recent advances and impending challenges for the radiopharmaceutical sciences in oncology - 29/05/24
Doi : 10.1016/S1470-2045(24)00030-5
Suzanne E Lapi, ProfPhD a, *, Peter J H Scott, ProfPhD b, *, Andrew M Scott, ProfMD c, d, e, f, *, Albert D Windhorst, ProfPhD g, h, *, Brian M Zeglis, ProfPhD i, j, k, *, May Abdel-Wahab, ProfMD m, Richard P Baum, ProfMD PhD q, John M Buatti, ProfMD r, Francesco Giammarile, ProfMD PhD n, s, Ana P Kiess, MD PhD t, Amirreza Jalilian, ProfPhD p, Peter Knoll, PhD o, Aruna Korde, PhD p, Jolanta Kunikowska, ProfMD PhD u, Sze Ting Lee, ProfMBBS c, d, e, f, Diana Paez, MD n, Jean-Luc Urbain, MD v, Jingjing Zhang, MD PhD w, x, Jason S Lewis, ProfPhD j, k, l, ⁎ 
a Departments of Radiology and Chemistry, O’Neal Comprehensive Cancer Center, University of Alabama, Birmingham, AL, USA
b Department of Radiology, University of Michigan, Ann Arbor, MI, USA
c Department of Molecular Imaging and Therapy, Austin Health, Melbourne, VIC, Australia
d Olivia Newton-John Cancer Research Institute, Melbourne, VIC, Australia
e School of Cancer Medicine, La Trobe University, Melbourne, VIC, Australia
f Department of Surgery, Faculty of Medicine, University of Melbourne, Melbourne, VIC, Australia
g Department of Radiology & Nuclear Medicine, Amsterdam UMC, Amsterdam, Netherlands
h Cancer Center Amsterdam, Vrije Universiteit, Amsterdam, Netherlands
i Department of Chemistry, Hunter College, City University of New York, New York City, NY, USA
j Department of Radiology, Memorial Sloan Kettering Cancer Center, New York City, NY, USA
k Department of Radiology, Weill Cornell Medical College, New York City, NY, USA
l Department of Pharmacology, Weill Cornell Medical College, New York City, NY, USA
m Division of Human Health, Department of Nuclear Sciences and Applications, International Atomic Energy Agency, Vienna, Austria
n Nuclear Medicine and Diagnostic Imaging Section, Division of Human Health, Department of Nuclear Sciences and Applications, International Atomic Energy Agency, Vienna, Austria
o Dosimetry and Medical Radiation Physics Section, Division of Human Health, Department of Nuclear Sciences and Applications, International Atomic Energy Agency, Vienna, Austria
p Radiochemistry and Radiotechnology Section, Division of Physical and Chemical Sciences, Department of Nuclear Sciences and Applications, International Atomic Energy Agency, Vienna, Austria
q Deutsche Klinik für Diagnostik (DKD Helios Klinik) Wiesbaden, Curanosticum MVZ Wiesbaden-Frankfurt, Center for Advanced Radiomolecular Precision Oncology, Germany
r Department of Radiation Oncology, University of Iowa Carver College of Medicine, Iowa City, IA, USA
s Centre Leon Bérard, Lyon, France
t Radiation Oncology and Molecular Radiation Sciences, Johns Hopkins University School of Medicine, Baltimore, MD, USA
u Nuclear Medicine Department, Medical University of Warsaw, Warsaw, Poland
v Department of Radiology–Nuclear Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA
w Department of Diagnostic Radiology, National University of Singapore, Singapore
x Clinical Imaging Research Centre, Nanomedicine Translational Research Program, Yong Loo Lin School of Medicine, National University of Singapore, Singapore
* Correspondence to: Prof Jason S Lewis, Department of Radiology, Memorial Sloan Kettering Cancer Center, New York City, NY 10065, USA Department of Radiology Memorial Sloan Kettering Cancer Center New York City NY 10065 USA
Summary |
This paper is the first of a Series on theranostics that summarises the current landscape of the radiopharmaceutical sciences as they pertain to oncology. In this Series paper, we describe exciting developments in radiochemistry and the production of radionuclides, the development and translation of theranostics, and the application of artificial intelligence to our field. These developments are catalysing growth in the use of radiopharmaceuticals to the benefit of patients worldwide. We also highlight some of the key issues to be addressed in the coming years to realise the full potential of radiopharmaceuticals to treat cancer.
Le texte complet de cet article est disponible en PDF.Plan
© 2024
Elsevier Ltd. Tous droits réservés.
Vol 25 - N° 6
P. e236-e249 - juin 2024 Retour au numéro
Article précédent
- The burden of cardiovascular disease and risk for subsequent major adverse cardiovascular events in survivors of childhood cancer: a prospective, longitudinal analysis from the St Jude Lifetime Cohort Study
- Rawan A Hammoud, Qi Liu, Stephanie B Dixon, Aron Onerup, Daniel A Mulrooney, I-Chan Huang, John L Jefferies, Isaac B Rhea, Kirsten K Ness, Matthew J Ehrhardt, Melissa M Hudson, Bonnie Ky, Nickhill Bhakta, Yadav Sapkota, Yutaka Yasui, Gregory T Armstrong
- Trends in nuclear medicine and the radiopharmaceutical sciences in oncology: workforce challenges and training in the age of theranostics
- Andrew M Scott, Brian M Zeglis, Suzanne E Lapi, Peter J H Scott, Albert D Windhorst, May Abdel-Wahab, Francesco Giammarile, Diana Paez, Amirreza Jalilian, Peter Knoll, Aruna Korde, Shrikant Vichare, Nayyereh Ayati, Sze Ting Lee, Serge K Lyashchenko, Jingjing Zhang, Jean Luc Urbain, Jason S Lewis
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?